1. Michi AN, Favetto PH, Kastelic J, et al. A review of sexually transmitted bovine trichomoniasis and campylobacteriosis affecting cattle reproductive health. Theriogenology 2016;85:781–791.
2. Yao C. Diagnosis of Tritrichomonas foetus-infected bulls, an ultimate approach to eradicate bovine trichomoniasis in US cattle? J Med Microbiol 2013;62:1–9.
3. Okafor CC, Strickland LG, Jones BM, et al. Prevalence of Tritrichomonas foetus in Tennessee bulls. Vet Parasitol 2017;243:169–175.
4. Rae DO, Crews JE, Greiner EC, et al. Epidemiology of Tritrichomonas foetus in beef bull populations in Florida. Theriogenology 2004;61:605–618.
5. Cobo ER, Favetto PH, Lane VM, et al. Sensitivity and specificity of culture and PCR of smegma samples of bulls experimentally infected with Tritrichomonas foetus. Theriogenology 2007;68:853–860.
6. Szonyi B, Srinath I, Schwartz A, et al. Spatio-temporal epidemiology of Tritrichomonas foetus infection in Texas bulls based on state-wide diagnostic laboratory data. Vet Parasitol 2012;186:450–455.
7. Perez A, Cobo E, Martinez A, et al. Bayesian estimation of Tritrichomonas foetus diagnostic test sensitivity and specificity in range beef bulls. Vet Parasitol 2006;142:159–162.
8. Martin SW, Shoukri M, Thorburn MA. Evaluating the health-status of herds based on tests applied to individuals. Prev Vet Med 1992;14:33–43.
9. Campero CM, Dubra CR, Bolondi A, et al. Two-step (culture and PCR) diagnostic approach for differentiation of non-T foetus trichomonads from genitalia of virgin beef bulls in Argentina. Vet Parasitol 2003;112:167–175.
10. Kimsey PB, Darien BJ, Kendrick JW, et al. Bovine trichomoniasisdiagnosis and treatment. J Am Vet Med Assoc 1980;177:616–619.
11. Skirrow S, Bondurant R, Farley J, et al. Efficacy of ipronidazole against trichomoniasis in beef bulls. J Am Vet Med Assoc 1985;187:405–407.
12. Workowski KA, Berman SM. Centers for Disease Control and Prevention Sexually Transmitted Disease Treatment Guidelines. Clin Infect Dis 2011;53:S59–S63.
13. Roe FJC. Metronidazole—review of uses and toxicity. J Antimicrob Chemother 1977;3:205–212.
14. Stover KR, Riche DM, Gandy CL, et al. What would we do without metronidazole? Am J Med Sci 2012;343:316–319.
15. Khodorovskî A, Zablotskî V, Timchenko K, et al. Study of the efficacy of metronidazole in trichomoniasis [in Russian]. Veterinariia 1970;10:104–105.
16. Gasparina G, Vagni M, Tardani A. Treatment of bovine trichomoniasis with metronidazole. Vet Rec 1963;75:940–943.
17. Golikov AV, Batiuta NV. Use of trichopol in trichomoniasis of sire bulls [in Russian]. Veterinariia 1972;11:37–40.
18. Reshetniak BZ, Bartenev VS, Bibikov FA, et al. Metronidazole—an effective drug for trichomoniasis in cattle [in Russian]. Veterinariia 1969;46:87–90.
19. Love D, Fajt VR, Hairgrove T, et al. Metronidazole for the treatment of Tritrichomonas foetus in bulls. BMC Vet Res 2017;13:107.
20. IARC. Metronidazole. IARC Monogr Eval Carcinog Risk Chem Man 1977;13:113–122.
21. Rustia M, Shubik P. Experimental induction of hepatomas, mammary-tumors, and other tumors with metronidazole in noninbred Sas:Mrc(Wi)Br rats. J Natl Cancer Inst 1979;63:863–868.
22. Roe FJC. Metronidazole: tumorigenicity studies in mice, rats and hamsters. In: Metronidazole: proceedings of the international metronidazole conference. Amsterdam: Excerpta Medica, 1977;132–137.
23. Roe FJC. A critical appraisal of the toxicology of metronidazole. In: Metronidazole: Royal Society of Medicine International Congress and Symposium. Series No. 18. London: Academic Press Inc and Royal Society of Medicine, 1979;215–222.
24. Roe FJC. Safety evaluation of metronidazole from the viewpoint of general toxicity and carcinogenicity: 1981 appraisal, in Proceedings. Eur Metronidazole Symp 1981;41–47.
25. IARC. Metronidazole. IARC Monogr Eval Carcinog Risk Chem Man 1982;(suppl 4):160–162.
26. FDA. Dimetridazole: opportunity for hearing. Fed Regist 1986;52:45244–45262.
27. Cavaliere A, Bacci M, Amorosi A, et al. Induction of lung-tumors and lymphomas in Balb/C Mice by metronidazole. Tumori 1983;69:379–382.
28. Cavaliere A, Bacci M, Vitali R. Induction of mammary tumors with metronidazole in female Sprague-Dawley rats. Tumori 1984;70:307–311.
29. Rust J. An assessment of metronidazole tumorigenicity: studies in the mouse and rat. In: Finegold SM, McFadqean JA, Roe FJC, eds. Metronidazole: Proceedings of the International Metronidazole Conference. Amsterdam: Excerpta Medica, 1977;138–144.
30. Rustia M, Shubik P. Induction of lung tumors and malignant lymphomas in mice by metronidazole. J Natl Cancer Inst 1972;48:721–729.
31. A-Kareem AM, Fleiszer DM, Richards GK, et al. Effect of long-term metronidazole (Mtz) therapy on experimental colon cancer in rats. J Surg Res 1984;36:547–552.
32. IARC. Metronidazole. IARC Monogr Eval Carcinog Risk Chem Man 1987;(suppl 7):250–251.
33. Roe F. The Leon-Golberg Memorial Lecture: recent advances in toxicology relevant to carcinogenesis—7 cameos. Food Chem Toxicol 1993;31:909–924.
34. Roe FJC. Are nutritionists worried about the epidemic of tumors in laboratory animals. Proc Nutr Soc 1981;40:57–65.
35. Brambilla G, Mattioli F, Robbiano L, et al. Update of carcinogenicity studies in animals and humans of 535 marketed pharmaceuticals. Mutat Res 2012;750:1–51.
36. Alden CL, Lynn A, Bourdeau A, et al. A critical review of the effectiveness of rodent pharmaceutical carcinogenesis testing in predicting for human risk. Vet Pathol 2011;48:772–784.
37. Jacobs AC, Hatfield KP. History of chronic toxicity and animal carcinogenicity studies for pharmaceuticals. Vet Pathol 2013;50:324–333.
38. Marone PA, Hall WC, Hayes AW. Reassessing the two-year rodent carcinogenicity bioassay: a review of the applicability to human risk and current perspectives. Regul Toxicol Pharmacol 2014;68:108–118.
39. Morton D, Sistare FD, Nambiar PR, et al. Regulatory Forum Commentary: alternative mouse models for future cancer risk assessment. Toxicol Pathol 2014;42:799–806.
40. Bendesky A, Menendez D, Ostrosky-Wegman P. Is metronidazole carcinogenic? Mutat Res 2002;511:133–144.
Advertisement